Review of ibandronate in the treatment of osteoporosis

Bibliography

• CRANNEY A, WELLS G, WILLAN A et al.: Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev (2002) 23:508–516.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev (2002) 23:517–523.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ZYTARUK N et al.: Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr. Rev (2002) 23:524–528.
   PubMed Web of Science ®Google Scholar
• REID IR, BROWN JP, BURKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl. J. Med. (2002) 346:653–661.
   PubMed Web of Science ®Google Scholar
• NEER RIVI, ARNAUD C, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl. I Med. (2001) 344:1434–1441.
   PubMedGoogle Scholar
• MEUNIER PJ, ROUX C, ORTOLANI S et al.: Strontium ranelate reduces the vertebral risk in women with postmenopausal osteoporosis. Osteoporos. mt. (2002) 13 (Suppl. 1):045.
   Google Scholar
• MUHLBAUER RC, BAUSS F, SCHENK R et al: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.j Bone Miner. Res. (1991) 6:1003–1011.
   Google Scholar
• FLEISCH H: The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos. mt. (1996) 6:166–170.
   PubMedGoogle Scholar
• MONIER-FAUGERE MC,FRIEDLER RM, BAUSS F et al.: A new bisphospohnate, BM-21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J. Bone Miner. Res. (1993) 11:1345–1355.
   Google Scholar
• MONIER-FAUGERE MC, GENG Z, PASCHALIS EP et al.: Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effect onbone morphometry and mineral properties. J. Bone Miner. Res. (1999) 14:1768–1778.
   PubMed Web of Science ®Google Scholar
• LALLA S, HOTHORN LA, HAAG N, BADER R, BAUSS F: Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos. hat. (1998) 8:97–103.
   PubMed Web of Science ®Google Scholar
• BAUSS F, WAGNER M, HOTHORN LH:Total administered dose of ibandronate determines effects on bone mass and architecture in ovariectomized aged rats. Rheumatol. (2002) 29:990–998.
   Google Scholar
• THIEBAUD D, HUSL B, JACQUET AF et al.: Effects of ibandronate IV bolus injection in healthy men and postmenopausal women. " Bone Miner. Res. (1997) 12\(Suppl. 1):5343.
   Google Scholar
• RAVN P, CLEMMESEN B, RIIS BJ, CHRISTIANSEN C: The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomised, double-blind, placebo-controlled dose-finding study. Bone (1996) 19:527–533
   PubMed Web of Science ®Google Scholar
• •Phase II, dose ranging study of oral ibandronate.
   Google Scholar
• SATO M, GRASSER W, ENDO N et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. I Clin. Invest. (1991) 88:2095–2105.
   Google Scholar
• HUGUES DE, WRIGHT KR, UY HL et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. (1995) 10:1478–1487.
   PubMedGoogle Scholar
• DUNFORD JE, THOMPSON K, COXON FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphophonates. Pharmacol. Exp. Ther. (2001) 296:235–242.
   PubMed Web of Science ®Google Scholar
• DOOLEY M, BALFOUR JA: Ibandronate. Drugs (1999) 57:101–108.
   PubMedGoogle Scholar
• RAVN P, NEUGEBAUER G,CHRISTIANSEN C: Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone (2002) 30:320–324.
   PubMedGoogle Scholar
• THIEBAUD D, BURKHARDTP, KRIEGBAUM H et al.: Three monthly intravenous injections of ibandronate in thetreatment of postmenopausal osteoporosis. Am. J. Med. (1997) 103:298–307.
   PubMed Web of Science ®Google Scholar
• RECKER RR, STAKKESTAD JA, FELSENBERG D et al.: a new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis: results of 3-year trial. Osteoporos. mt. (2000) 11 (Suppl. 2):5209.
   Google Scholar
• ••Phase III, randomised, placebo-controlledtrial of intravenous ibandronate, with vertebral fracture risk as the main endpoint.
   Google Scholar
• RIIS BJ, ISE J, VON STEIN T,BAGGER Y, CHRISTIANSEN C: Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J. Bone Miner. Res. (2001) 16:1871–1878.
   PubMed Web of Science ®Google Scholar
• •Phase II, randomised, crossover trial of oral ibandronate, comparing daily to intermittent regimens.
   Google Scholar
• DELMAS PD, RECKER RR,STAKKESTAD JA et al.: Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal Phase III study. Osteoporos. Int. (2002) 17\(Suppl. 1):515.
   Google Scholar
• ••Phase III, randomised, placebo-controlledtrial of oral ibandronate, with vertebral fracture risk as the main endpoint.
   Google Scholar
• ADAMI S, DELMAS P, FELSENBERG D et al.: Three monthly 23 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos. hat (2002) 17\(Suppl. 1):514.
   Google Scholar
• PECHERSTORFER M, LUDWIG H, SCHLOSSER K et al: Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J. Bone Miner. Res. (1996) 11:587-593.Affiliation
   Google Scholar